Ainos Details Partner-Funded VELDONA Development and Revenue Opportunities, Reinforcing Focus on Chemical Intelligence

HOUSTON, TX / ACCESS Newswire / September 28, 2026 / Ainos, Inc. (NASDAQ:AIMD)(NASDAQ:AIMDW) ("Ainos" or the "Company") today detailed the financial and strategic benefits of the VELDONA® License Agreement announced on September 24, 2026 (the "Agreement"). Ainos expects to complete the agreed contractual delivery shortly, with an initial license fee of $600,000 payable within 15 business days after the applicable payment conditions are satisfied. This payment does not depend on completion of future clinical trials or receipt of marketing approval.

The pharmaceutical development partner identified in the September 24 announcement (the "licensee") will fund and execute the clinical and regulatory activities assigned to it for the two initial globally licensed indications, Sjögren's disease and thrombocytopenia. This structure reduces Ainos' need to independently finance subsequent development, expand specialist teams and devote additional management resources to pharmaceutical execution, supporting the Company's priority investment in Chemical Intelligence.